Interventional Ischemic Stroke Treatment – A (R)evolution

Die interventionelle Behandlung des ischämischen Schlaganfalls – eine (R)evolution

Authors
B. Friedrich¹, M. Gawlitza², J. Fahnert¹, U. Quäschling², T. Kahn¹, D. Lobsien², K.-T. Hoffmann²

Affiliations
¹ Department of Diagnostic and Interventional Radiology, University Hospital Leipzig, Germany
² Department of Neuroradiology, University Hospital Leipzig, Germany

Key words
- brain
- angiography
- ischemia/infarction

Abstract

In recent years ischemic stroke caused by an intracranial vessel occlusion has become a treatable disease. Over decades intravenous thrombolysis by recombinant tissue plasminogen activator was the only accepted causal treatment of ischemic stroke supported by the results of randomized, controlled trials. However, there has been continuous development of endovascular treatment strategies over recent years. Today there are 5 prospective, randomized multicenter studies showing the highly significant superiority of endovascular, mechanical recanalization over intravenous thrombolysis in cases of acute occlusion of an intracranial vessel of the anterior circulation. In all those studies endovascular treatment resulted in a tremendous increase in functional independence together with a reduction of mortality without a significant increase in complications. This article reviews the developments resulting in the current data and gives an overview of the present studies focusing on endovascular stroke treatment.

Key Points:
- In the last 20 years ischemic stroke due to an main stem occlusion has become a potentially treatable disease.
- Several in 2015 published randomized Multicentric trials could prove the superiority of endovascular, mechanical recanalization over i.v. thrombolysis alone.
- Acute ischemic stroke due to a main stem occlusion should be treated with swift endovascular stent-retriever based recanalization in specialized neurovascular centers.

Zusammenfassung


Introduction

Ischemic stroke is an acute, potentially life-threatening disease. It is caused by cerebral hypoperfusion primarily due to thromboembolic or local thrombotic vascular occlusions [1–4]. If the occlusion and the resulting hypoperfusion are present for a long time, neuronal death occurs, resulting in irreversible damage to the affected brain areas [5]. Approximately 1.3 million people among the
740 million inhabitants in Europe suffer from a stroke each year [6, 7]. Since ischemic stroke causes high morbidity as a result of constant neurological deficits that result in possible lifelong dependence on nursing and physiotherapeutic care, strokes incur very high costs of approx. 26 billion Euros each year in Europe [7]. To 1995, the diagnosis of a severe ischemic stroke almost always represented an individual health catastrophe that simply had to be accepted since no causal treatments were available. The only option was the best possible conservative treatment ("supportive care").

Intravenous thrombolysis

The breakthrough in the treatment of ischemic stroke came in 1995. The NINDS study led by the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group was able to show in 624 patients that treatment with 0.9 mg/kg intravenously administered recombinant tissue plasminogen activator (rtPA) resulted in a good clinical outcome in 39 % of patients (mRS< 3, largely independent in daily activities) compared to only 26 % in the placebo group [8]. This was the first indication of effective treatment of acute ischemic stroke. Candidates for IV thrombolysis were patients with symptom onset of less than 3 hours with no recent history of bleeding or operation. Contraindications were a severe coagulation defect or treatment with anticoagulants as well as arterial hypertension with a systolic RR > 185 mmHg or diastolic RR > 110 mmHg. Intracranial bleeding – as an absolute contraindication for thrombolysis – as well as infarct demarcation had to be ruled out via non-contrast cranial computed tomography. As expected, the most frequent side effects of IV thrombolysis were bleeding complications, in particular intracranial bleeding. With 6.4 % vs. 0.6 %, this occurred significantly more frequently after rtPA than after administration of the placebo. In the same year the "European Cooperative Acute Stroke Study" (ECASS) was published. In the target population, thrombolysis showed significant improvement of functional independence after 90 days. However, this result could not be confirmed in the intention-to-treat analysis. The rate of intracranial bleeding also increased significantly after rtPA as in the NINDS study [9]. Nonetheless, as a result of these two studies, the administration of rtPA for treating ischemic stroke was approved by the American Food and Drug Administration (FDA). In the following years, IV thrombolysis became established worldwide as a standard for the acute treatment of ischemic stroke. Despite the initially great optimism, it was seen relatively quickly that only approximately 3 – 5 % of all stroke patients could undergo thrombolysis [10 – 12]. This was due to the list of contraindications as well as the narrow time window of 3 hours. For this reason, the studies at the start of the 2000s concentrated on expanding the time window. A pooled evaluation of multiple studies yielded the first indications that treatment with rtPA could be effective beyond the time window of 3 hours [13]. In 2008, the third "European Cooperative Acute Stroke Study" (ECASS III study) was able to show the benefit of IV rtPA for the treatment of ischemic stroke even up to a time window of 4.5 hours after the onset of symptoms (Fig. 1) [14]. The treatment time window that was consequently expanded to 4.5 hours was confirmed in practical application by the treatment study "Safe Implementation of Thrombolysis in Stroke – Internatio nal Stroke Thrombolysis Register" (SITS-ISTR) [15]. Despite the expanded inclusion criteria, patients with the most severe cases of stroke – caused by main stem occlusion at the circle of Willis – profited only comparatively little from intravenous thrombolysis [16, 17]. The absolute risk reduction with respect to death or permanent disability was only between 13 % (NINDS) and 7 % (ECASS III) depending on the study [8, 14].

Fig. 1 Results of the most important intravenous thrombolysis studies (rtPA = recombinant tissue plasminogen activator).
The beginnings of interventional treatment

Due to the often poor response of patients with intracranial main stem occlusion to IV thrombolysis, attempts have increasingly been made to treat these occlusions intracereally with catheters. The local application of fibrinolytic substances via catheter immediately at or in the thrombus represented the start of interventional stroke treatment [18]. After several promising case reports and series were published, the PROACT II study was able to show in 1999 that the local application of urokinase achieved a substantial increase in the success rate of recanalization [19]. However, the clinical success lagged behind expectations and IV thrombolysis via rtPA continued to be the standard treatment. Nonetheless, the development of interventional stroke therapy continued, in the hope of further improving the clinical results as a result of improved techniques. An obvious idea was to retrieve the thrombus from the vessel instead of dissolving it in order to achieve immediate recanalization. The MERCI Retriever (Concentric Medical, USA) was the first device developed specifically for interventional stroke therapy. This corkscrew-like nitinol spiral was approved in 2004 by the FDA for the treatment of acute main stem occlusions within 8 hours of the onset of symptoms in the presence of contraindications for IV thrombolysis [20]. CE certification of the CATCH device (Balt Extrusion, France), a derivative of the LEO stent, in which the stent is suspended in a proximal concentric position from an insertion wire and is distally closed, was granted a year later. Both devices were based on the idea of initially passing the thrombus, placing the device distal to the thrombus, and then removing it via a retraction maneuver. This recanalization method was successful: The MERCI and MULTI MERCI studies published in 2005 and 2008 showed a significantly higher recanalization rate of the MERCI device compared to the PROACT II study so that use of the MERCI device in patients with contraindications to IV rtPA soon found broad acceptance [21, 22]. However, the recanalization rates of 45–60 % in both studies were still not satisfactory. The embolism rate in other initially unaffected vascular territories in animal studies of up to 18 % was also comparatively high [23]. These high embolism rates could not be confirmed in clinical use. In 2006, Penumbra (USA) presented a completely different approach: Use of an aspiration catheter with a dedicated aspiration pump together with a specially designed wire for fragmentation of the thrombus, called a separator [24]. The function principle was to suction the thrombus from a proximal position out of the vessel while inducing simultaneous fragmentation with the separator. This system was able to achieve recanalization rates of up to 80 % in studies [25]. Thus, multiple competing mechanical recanalization methods for acute ischemic stroke for which an effectiveness in the presence of contraindications to IV rtPA was shown were available from the middle to the end of the first decade of the 2000s. However, IV thrombolysis remained the global gold standard in first-line therapy.

The era of the stent retriever

The breakthrough in interventional stroke therapy came in 2008, more or less as a coincidence, as is often the case in medicine [26]. On the afternoon of March 3, 2008, a 67-year-old patient suffering from a severe stroke caused by proximal occlusion of the middle cerebral artery was admitted to the Katharinenhospital in Stuttgart. 30 minutes after the start of IV thrombolysis, the patient’s symptoms had not improved so that the indication for endovascular therapy was determined. After initial recanalization attempts with the above-mentioned approved devices remained unsuccessful, an interventional tool originally intended for a completely different indication, i.e. a stent, was implemented. The Solitaire Stent (ev3, USA) was originally approved in Europe in 2007 for stent-assisted coiling of intracranial aneurysms. In this case, i.e., the first off-label use of the stent in an acute stroke situation, the stent was released in the thrombus, but not detached and left in the vessel as originally intended by the manufacturer. After several minutes of allowing the stent to take effect by embedding in the thrombus, the stent was then drawn into the guide catheter under aspiration and removed. The result was immediate reopening of the occluded vessel by removing the thrombus. Despite the previous unsuccessful recanalization attempts, the intervention time remained less than an hour. After the end of the intervention, the patient awoke with only mild neurological symptoms that resolved fully within 3 months. This case launched a new era of interventional stroke therapy. The Solitaire Stent quickly became widely used as a thrombectomy device. Consequently, a specific variant of the Solitaire designed for thrombectomy (Solitaire FR) was developed and CE-certified in July 2009. In 2012 the experience of users was able to be proven in a first study: Use of the Solitaire Stent resulted in significantly higher recanalization rates than the previously used standard device, the MERCI Retriever, and in a significantly better clinical outcome [27]. Due to the good success of the Solitaire as a stent retriever with high recanalization rates, multiple new devices with a similar function were developed in parallel, such as the TREVO (Concentric Medical), ReVive (Micrus, Codman and Shurtleff, USA) or pREset (phenox, Germany), to name a few of the most common ones. After the use of stent retrievers proved to be safe and technically comparatively simple and recanalization rates of up to 90 % were reported in individual case series [28, 29], the question was increasingly posed as to whether this interventional treatment could be more than a last option in hopeless cases and whether it could be an alternative to the current standard of first-line therapy of ischemic stroke, i.e., thrombolysis via IV rtPA.

The ‘backlash’ in 2013

At the beginning of February 2013, three randomized multicenter studies for clarifying the question of whether interventional stroke therapy is superior to IV thrombolysis appeared in an issue of the New England Journal of Medicine, i.e., “Interventional Management of Stroke Trial” (IMS...
Friedrich B et al. Interventional Ischemic Stroke: Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) and "Intra-Arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke" (SYNTHESIS) [30–32]. All three studies independently came to the conclusion that the clinical results of intraarterial stroke therapy are only equivalent to IV thrombolysis and are not superior. These results contradicted in many respects the experience particularly of interventional neuroradiologists and neurologists treating strokes on a daily basis, thus igniting an extremely critical discussion. Why were the study results negative or the studies not capable of proving the superiority of intraarterial therapy? Major weaknesses in the planning, implementation, and interpretability of these three studies were identified as causes. IMS III was an international multicenter study with the goal of proving the superiority of intraarterial stroke therapy compared to standard therapy via IV rtPA alone. In total, 656 patients were included before the study was prematurely ended. Due to the very long recruiting period, every device approved for the indication of intraarterial stroke therapy was also approved for use in the study. However, the majority of patients randomized in the interventional arm were treated exclusively with the local application of rtPA (N = 142) followed by older devices like the MERCI Retriever (N = 95). Superior, modern stent retrievers were only used for an extremely small number of patients (N = 5, 0.8%) [30, 33]. This resulted in significantly worse recanalization rates of less than 50% compared to the stent retriever studies. A further significant weakness was the selection of patients. The pragmatic approach of randomizing patients exclusively according to their clinical presentation and after exclusion of bleeding via non-contrast CT was selected. This resulted in almost one fourth of patients (24%) randomized into the intraarterial arm not receiving intraarterial therapy since no treatable vascular occlusion could be detected on angiography. The SYNTHESIS study, an Italian multicenter study, also missed the defined target of proving the superiority of intraarterial therapy compared to IV therapy in relation to the clinical outcome of achieving the greatest possible independence in the daily routine after 90 days. In total, 362 patients were included in this study and randomized into intraarterial versus IV therapy. Significantly outdated techniques were also used in this study (fragmentation with a microwire, local thrombolysis, use of a stent retriever only in 5%) in 2013. Recanalization results were not reported [32]. Finally the MR RESCUE study examined whether intraarterial therapy is superior to standard therapy if multimodal MRI imaging is used for selection. In total, 127 patients were included, and intraarterial treatment was performed either via MERCI retriever or Penumbra aspiration system. Successful recanalization could be achieved in 67% of cases and again intraarterial therapy was shown not to be superior to IV therapy in the clinical 90-day result. In addition to the already outdated recanalization methods used in the MR RESCUE study, time management is another possible obstacle to the success of the study. The average time from the onset of symptoms to groin puncture and the start of the intervention was more than 6 hours (381 +/- 74 minutes) [31].

These three studies published simultaneously in one of the most well-respected medical journals initially represented a harsh backlash for endovascular stroke therapy. Due to the apparent study design flaws that became evident during implementation, new prospective randomized multicenter studies were planned partially in parallel regarding the question of whether intraarterial therapy using modern (current) recanalization techniques and devices is indeed superior to IV therapy.

The breakthrough for interventional stroke therapy

In October 2014, the results of the first new recanalization study, “The multicenter collaboration for endovascular treatment of acute ischemic stroke in the Netherlands” (MR CLEAN), were presented at the 9th World Stroke Conference in Istanbul. This Dutch multicenter study randomized 500 patients with a verified occlusion of a main stem of the anterior circulation and symptom onset of less than 6 hours either into standard therapy or additional mechanical recanalization (Table 1, 2) [34]. In principle, there were no specifications regarding recanalization devices. Physicians were able to make decisions based on the situation and their own experience. In 81.5% of cases mechanical recanalization via modern stent retriever was selected (Table 3). Successful recanalization, defined as a thrombolysis in cerebral infarction (TICI) value of 2b or 3, was achieved in 58.7% of cases. This resulted in a functional independence (modified Rankin Scale mRS = 2) of 32.6% of patients after 90 days (Table 4). Patients treated only with IV thrombolysis reached this primary end point in only 19.1% of cases (Fig. 2). These results were thus able to reflect for the first time the already empirically proven reality: The use of mechanical recanalization in patients with a proven main stem occlusion was superior to IV thrombolysis alone within a time window of 6 hours with high significance and almost doubled the probability of the patient being able to live an independent life 90 days after a stroke. The two groups had a 90-day mortality rate of 22% and 21%, respectively. The other side effect profile did not show a significant difference between the two treatment groups particularly with respect to bleeding complications.

After this study showed the superiority of mechanical recanalization for the first time, 4 parallel studies (ESCAPE, EXTEND IA, SWIFT PRIME and REVASCAT) with largely the same goal were terminated for ethical reasons and were analyzed. The results were initially presented at conferences and were then also published in the New England Journal of Medicine in the first half of 2015. All studies differed with respect to design, but largely came to the same result:

- In addition to detected vascular occlusion, ESCAPE selected patients based on the degree of collateralization using multiphasic CTA and also had the biggest time window of 12 hours. Recanalization TICI 2b/3 was achieved in 72.4% of cases and 53% of patients were functionally independent 90 days after recanalization in contrast to 29.3% after IV thrombolysis. The mortality rate was able to be cut in half by endovascular recanalization [35].
EXTEND-IA was characterized by the most complex imaging selection method: In addition to a detected vascular occlusion, CT perfusion imaging had to show a small infarct core (< 70 ml) and a large salvageable penumbra (> 1.2 times the infarct core). The time window was 6 hours. Moreover, the Solitaire Stent Retriever was the only approved device. Successful recanalization was achieved in this study in 86 % of cases, resulting in a 90-day mRS ≤ 2 in 71 % of cases compared to 40 % after IV thrombolysis. The mortality rate was again cut in half by intraarterial therapy [36].

In the first half of the study, SWIFT PRIME included patients with a detected vascular occlusion and a salvageable penumbra detected via perfusion imaging within 6 hours. In the second half of the study, perfusion imaging was no longer a mandatory inclusion criterion. Patients were treated with the Solitaire. Cervical carotid occlusions requiring stenting were an exclusion criterion.

### Table 1  Study inclusion criteria.

<table>
<thead>
<tr>
<th>MR CLEAN</th>
<th>ESCAPE</th>
<th>EXTEND-IA</th>
<th>SWIFT-PRIME</th>
<th>REVASCAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>time window</td>
<td>6 h</td>
<td>12 h</td>
<td>6 h (intervention ended after 8 h)</td>
<td>6 h</td>
</tr>
<tr>
<td>NIHSS</td>
<td>&gt; 2</td>
<td>&gt; 5</td>
<td>no data</td>
<td>&gt; ≥ 8 and &lt; 30</td>
</tr>
<tr>
<td>imaging</td>
<td>NCCT + CTA / MRI + MRA / DSA</td>
<td>NCCT + CTA (multiphasic)</td>
<td>NCCT + CTA + CTP</td>
<td>NCCT + CTA / MRI + MRA (perfusion imaging in the first 71 patients)</td>
</tr>
<tr>
<td>occlusion</td>
<td>carotid-T, M1 – 2, A1; ACI stent+PTA no exclusion</td>
<td>carotid-T, M1 or M1 equivalent (2 or more M2 branches); ACI stent+PTA no exclusion</td>
<td>carotid-T, M1 – 2; ACI stent+PTA no exclusion</td>
<td>carotid-T, M1; only PTA of ACI allowed</td>
</tr>
<tr>
<td>functional imaging</td>
<td>–</td>
<td>moderate to good collateralization</td>
<td>penumbra: tmax &gt; 6 s; infarct core: &lt; 70 ml + rCBF &lt; 30 %; mismatch: &gt; 1.2 + &gt; 10 ml</td>
<td>for the first 71 patients: Mismatch &gt; 1.8 + &gt; 15 ml + infarct core &lt; 50 ml</td>
</tr>
</tbody>
</table>

NIHSS = National Institute Of Health Stroke Scale; NCCT = non-contrast cranial CT; CTA = CT angiography; A1 = 1st segment of the anterior cerebral artery; M1, M2 = 1st or 2nd segment of the middle cerebral artery; ACI = internal carotid artery; PTA = percutaneous transluminal angioplasty; rCBF = relative cerebral blood flow, Tmax = time to bolus maximum.

### Table 2  Location of occlusion in study patients.

<table>
<thead>
<tr>
<th>MR CLEAN</th>
<th>ESCAPE</th>
<th>EXTEND-IA</th>
<th>SWIFT-PRIME</th>
<th>REVASCAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>carotid-T</td>
<td>27 %</td>
<td>27 %</td>
<td>31 %</td>
<td>18 %</td>
</tr>
<tr>
<td>M1</td>
<td>64 %</td>
<td>70 %</td>
<td>54 %</td>
<td>72 %</td>
</tr>
<tr>
<td>M2</td>
<td>8 %</td>
<td>3 %</td>
<td>15 %</td>
<td>10 %</td>
</tr>
<tr>
<td>A1 / A2</td>
<td>1 %</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>cervical ACI (stenosis/occlusion)</td>
<td>29 %</td>
<td>12.7 %</td>
<td>8.6 %</td>
<td>4 % (only PTA)</td>
</tr>
</tbody>
</table>

The numbers form averages for the particular study collectives. Abbreviations: M1, M2 = 1st or 2nd segment of the middle cerebral artery; A1, A2 = 1st or 2nd segment of the anterior cerebral artery; PTA = percutaneous transluminal angioplasty.

### Table 3  Description of the interventions in the studies.

<table>
<thead>
<tr>
<th>MR CLEAN</th>
<th>ESCAPE</th>
<th>EXTEND-IA</th>
<th>SWIFT-PRIME</th>
<th>REVASCAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV rtPA</td>
<td>not a mandatory inclusion criterion</td>
<td>not a mandatory inclusion criterion</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>device</td>
<td>all (81.5 % stent retriever)</td>
<td>all (86.1 % stent retriever)</td>
<td>solitaire</td>
<td>solitaire</td>
</tr>
<tr>
<td>anesthesia</td>
<td>37.8 % IN</td>
<td>9.1 % IN</td>
<td>36 % IN</td>
<td>37 % IN</td>
</tr>
<tr>
<td>times</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>onset of symptoms – rtPA [min]</td>
<td>86</td>
<td>115</td>
<td>145</td>
<td>117</td>
</tr>
<tr>
<td>onset of symptoms – groin puncture [min]</td>
<td>260</td>
<td>185</td>
<td>210</td>
<td>224</td>
</tr>
<tr>
<td>imaging – groin puncture [min]</td>
<td>n.a.</td>
<td>51</td>
<td>93</td>
<td>57</td>
</tr>
<tr>
<td>onset of symptoms – reperfusion [min]</td>
<td>n.a.</td>
<td>241</td>
<td>248</td>
<td>252</td>
</tr>
</tbody>
</table>

rtPA = recombinant tissue plasminogen activator; IN = endotracheal anesthesia; IA = intraarterial.
88% of patients were able to be successfully recanalized. 60% of patients were functionally independent after i.a. therapy compared to 35% after IV thrombolysis [37]. REVASCAT included patients within 8 hours of the onset of symptoms. To be randomized, the patients were not allowed to have experienced symptom improvement 30 minutes after the start of IV thrombolysis. Recanalization was also only performed with the Solitaire and was successful in 65.7% of cases. 43.7% of patients showed a 90-day mRS ≤ 2 – a result that was achieved in only 28.2% of patients after IV thrombolysis [38].

The significantly higher rates of patients with a functionally independent life after 90 days in SWIFT PRIME and EXTEND-IA compared to MR CLEAN can probably be explained by the very different rate of pathologies in the region of the cervical carotid artery and the carotid-T (Table 2). Patient selection was also significantly aligned with multimodal imaging particularly in EXTEND-IA in order to select patients who would most probably profit from endovascular recanalization. Based on this fact, results in the clinical reality will tend to correspond more with the results of the MR CLEAN study.

Thus, 5 studies of the highest evidence class have been available since April 2015 that were able to independently prove the superiority of intraarterial recanalization via stent retriever compared to IV thrombolysis in the case of acute occlusion of the anterior cerebral circulation and this according to the results of the currently available subgroup analyses with a time window of up to at least 6 hours (see the following section “The future”) and independently of patient age (patients over 80 years or 65 years, depending on the inclusion criteria, profit as much as younger patients [34–38]). Due to the overwhelming evidence for recanalization with a number-needed-to-treat for a functionally independent life of 3–5 [39], a consensus statement of multiple European and American professional societies was quickly published with the clear recommendation to implement mechanical recanalization as the standard treatment method (Fig. 3) [40, 41].

### Table 4  Results of the studies.

<table>
<thead>
<tr>
<th></th>
<th>MR CLEAN</th>
<th>ESCAPE</th>
<th>EXTEND-IA</th>
<th>SWIFT-PRIME</th>
<th>REVASCAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>number of patients</td>
<td>500</td>
<td>316</td>
<td>70</td>
<td>196</td>
<td>206</td>
</tr>
<tr>
<td>successful recanalization (TICI 2b/3)</td>
<td>58.7%</td>
<td>72.4%</td>
<td>86%</td>
<td>88%</td>
<td>65.7%</td>
</tr>
<tr>
<td>outcome 90d mRS ≤ 2</td>
<td>rtPA</td>
<td>intervention</td>
<td>mortality</td>
<td>rtPA</td>
<td>intervention</td>
</tr>
<tr>
<td>rtPA</td>
<td>19.1%</td>
<td>32.6%</td>
<td>22%</td>
<td>21%</td>
<td>22%</td>
</tr>
<tr>
<td>intervention</td>
<td>29.3%</td>
<td>53%</td>
<td>19%</td>
<td>10%</td>
<td>19%</td>
</tr>
<tr>
<td>mortality</td>
<td>40%</td>
<td>71%</td>
<td>20%</td>
<td>9%</td>
<td>9%</td>
</tr>
<tr>
<td>rtPA</td>
<td>35%</td>
<td>60%</td>
<td>12%</td>
<td>9%</td>
<td>12%</td>
</tr>
<tr>
<td>intervention</td>
<td>28.2%</td>
<td>43.7%</td>
<td>15.5%</td>
<td>18.4%</td>
<td>15.5%</td>
</tr>
<tr>
<td>sICH</td>
<td>n.a.</td>
<td>2.7%</td>
<td>3%</td>
<td>1.9%</td>
<td>1.9%</td>
</tr>
<tr>
<td>intervention</td>
<td>n.a.</td>
<td>3.6%</td>
<td>0%</td>
<td>0%</td>
<td>1.9%</td>
</tr>
</tbody>
</table>

Abbreviations: TICI = Thrombolysis in Cerebral Infarction Score; mRS = modified Rankin Scale; rtPA = recombinant tissue plasminogen activator; sICH = symptomatic intracranial hemorrhage.
The future

A joint guideline of multiple European professional societies (ESO, ESMINT and ESNR) regarding interventional stroke therapy which will include the results of two additional studies (THRACE, THERAPY) only presented at conferences to date is expected to still be published this year.

Despite or partly because of the impressive data, there are still some questions regarding clinical practice and future studies:

1. How will patients be distributed in the future? Given the estimated 10,000 patients who are considered each year for recanalization in Germany, it may not be necessary to increase the number of neuroradiological-neurovascular centers. However, quick diagnosis and immediate transfer from primary care to neurovascular centers must be significantly improved and the resources in these centers for interventional stroke therapy must be adapted to an increasing number of cases.

2. Is “time window” still current as a term and selection criterion? A time window has always been a surrogate parameter for the probability of still vital brain tissue. Today there are imaging methods with which the vitality of brain tissue can be visualized. In the ESCAPE study, for example, 15.5% of patients were treated later than 6 hours after the onset of symptoms. It seems possible to identify patients who would profit after long intervals as much as patients with a shorter symptom duration on the basis of results of selection criteria based on imaging, e.g., collateralization analysis [35].

3. What are the treatment options for patients suffering from a “wake-up” stroke (with an unknown onset of symptoms)? The ability to treat this patient collective with interventional procedures must be examined in future studies with multimodal imaging.

4. Which types of occlusion profit from intraarterial treatment? According to the currently available studies, carotid-T and M1 occlusions undoubtedly profit from recanalization. However, the outcome of the use of thrombectomy in more distal occlusions has not yet be definitively determined. Nonetheless, individual case series have been able to show excellent results in some more distal occlusions without a significant increase in complications [42, 43]. However, there are no random-
Summary

Interventional therapy of ischemic stroke due to an intracranial main stem occlusion of the anterior circulation via stent retriever-based recanalization within 6 hours of the onset of symptoms is significantly superior to thrombolytic therapy via IV rtPA alone and increases the probability of patients leading a functionally independent life with a simultaneous reduction of mortality. It should therefore be viewed as the standard therapy to be provided nationwide in neuroradiology departments.

References

46 van der Hoeven EJRF, Schonewille WJ, Vos JA et al. The Basilar Artery International Cooperation Study (BASICS): study protocol for a randomised controlled trial. Trials 2013; 14: 200